MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Strona główna・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

6.62 -1.63

Buy Sell

Overview

Share price change

24h

Current

Min

6.58

Max

6.64

Key metrics
By Trading Economics
Income	5.1M 5.1M
Sales	18M 163M
Profit margin	3.113
Employees	580
EBITDA	7.2M 28M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+212.22% upside

Dividends
By Dow Jones
Next Earnings	3 lis 2025

Market Stats
By TradingEconomics
Market Cap	-355M 1.5B
Previous open	8.25
Previous close	6.62

News Sentiment

By Acuity

100%

356 / 371 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 paź 2025, 18:13 UTC

Major Market Movers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 paź 2025, 17:05 UTC

Major Market Movers

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 paź 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

18 paź 2025, 07:00 UTC

Earnings

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17 paź 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 paź 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 paź 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 paź 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 paź 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 paź 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 paź 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 paź 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 paź 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 paź 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 paź 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 paź 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 paź 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 paź 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 paź 2025, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

17 paź 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 paź 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 paź 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 paź 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 paź 2025, 15:56 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 paź 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

212.22% upside

12 Months Forecast

Average 20.7 USD 212.22%

High 30 USD

Low 8 USD

Based on 10 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

356 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.